



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Marstacimab

<b>Cat. No.:</b>	HY-P99725
<b>CAS No.:</b>	1985638-39-8
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia <sup>[1][2]</sup> .									
<b>In Vitro</b>	<p>Marstacimab (20, 50 and 100 nmol/L) decreases rotational thromboelastometry (ROTEM) corn trypsin (CT) of the whole blood that obtained from haemophilia participants<sup>[1]</sup>.</p> <p>Marstacimab (16 µg/mL) decreases the lag time and increases thrombin generation of human nonhemophilic plateletpoor plasma samples in vitro<sup>[2]</sup>.</p> <p>Marstacimab (16 µg/mL) increases the peak thrombin in both hemophilia A and hemophilia B plasma samples in vitro<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>Marstacimab (0.5 mg/kg; i.v., once) does not affect the blood flow situation in mouse acute bleeding models<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Acute bleeding hemophilia A mouse models<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection, 0.5 mg/kg, once, before tail clip</td> </tr> <tr> <td>Result:</td> <td>Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.</td> </tr> </table>		Animal Model:	Acute bleeding hemophilia A mouse models <sup>[2]</sup>	Dosage:	0.5 mg/kg	Administration:	Intravenous injection, 0.5 mg/kg, once, before tail clip	Result:	Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
Animal Model:	Acute bleeding hemophilia A mouse models <sup>[2]</sup>									
Dosage:	0.5 mg/kg									
Administration:	Intravenous injection, 0.5 mg/kg, once, before tail clip									
Result:	Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.									

### REFERENCES

[1]. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. *Haemophilia*. 2019 Sep;25(5):797-806.

[2]. Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. *Res Pract Thromb Haemost*. 2022 Mar 16;6(2):e12679.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA